VYNE / VYNE Gains on Preclinical Data for IPF Candidate

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis. more_horizontal

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the num more_horizontal

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical compa more_horizontal

Are these under $1 penny stocks worth buying this month? The post 3 Penny Stocks Under $1 That Are on Fire Today  appeared first on Penny Stocks to B more_horizontal

VYNE Therapeutics Inc (NASDAQ: VYNE) announced positive preclinical data from its VYN201 program in the rheumatoid arthritis (RA) animal model. The more_horizontal

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor more_horizontal

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor more_horizontal

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor more_horizontal